(BUD) Anheuser Busch Inbev - Overview
Stock: Beer, Spirits, Ready-To-Drink, Non-Alcohol Beverages
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 1.48% |
| Yield on Cost 5y | 1.57% |
| Yield CAGR 5y | 12.66% |
| Payout Consistency | 90.4% |
| Payout Ratio | 34.5% |
| Risk 5d forecast | |
|---|---|
| Volatility | 21.7% |
| Relative Tail Risk | -6.29% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.71 |
| Alpha | 50.79 |
| Character TTM | |
|---|---|
| Beta | 0.214 |
| Beta Downside | 0.089 |
| Drawdowns 3y | |
|---|---|
| Max DD | 31.55% |
| CAGR/Max DD | 0.35 |
Description: BUD Anheuser Busch Inbev January 28, 2026
Anheuser-Busch InBev (NYSE:BUD) is a global brewer that markets, distributes and sells roughly 500 beer brands-including Budweiser, Corona Extra, Stella Artois and Michelob Ultra-across North America, Latin America, Europe, the Middle East, Africa and the Asia-Pacific, while also offering spirits-based ready-to-drink (RTD) and non-alcoholic beverages such as Cutwater and NÜTRL.
In its most recent quarter (Q4 FY 2025), AB InBev generated net revenue of **$63.5 billion**, posted an adjusted EBITDA margin of **18.5 %**, and delivered **$5.2 billion** of free cash flow, despite a **2 % YoY decline in comparable volume** that was partially offset by a **12 % rise in RTD sales**, led by the Cutwater line.
Key macro drivers for the brewer include continued pressure on volume from stagnant disposable income in the United States (beer volume down ~3 % YoY) and a shift toward premium and low-alcohol categories, while emerging-market growth remains modest as inflation erodes purchasing power. The sector’s broader trend of expanding RTD and non-alcoholic offerings is expected to provide a higher-margin growth tail for large brewers.
For a deeper, data-driven assessment of AB InBev’s valuation dynamics, you may find the analytics on ValueRay worth exploring.
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income: 9.85b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA 0.77 > 1.0 |
| NWC/Revenue: -11.36% < 20% (prev -39.36%; Δ 28.01% < -1%) |
| CFO/TA 0.07 > 3% & CFO 15.19b > Net Income 9.85b |
| Net Debt (61.00b) to EBITDA (24.56b): 2.48 < 3 |
| Current Ratio: 0.70 > 1.5 & < 3 |
| Outstanding Shares: last quarter (1.99b) vs 12m ago -2.79% < -2% |
| Gross Margin: 55.92% > 18% (prev 0.46%; Δ 5546 % > 0.5%) |
| Asset Turnover: 41.62% > 50% (prev 34.18%; Δ 7.44% > 0%) |
| Interest Coverage Ratio: 1.79 > 6 (EBITDA TTM 24.56b / Interest Expense TTM 8.48b) |
Altman Z'' 1.61
| A: -0.05 (Total Current Assets 23.00b - Total Current Liabilities 33.07b) / Total Assets 206.64b |
| B: 0.23 (Retained Earnings 46.58b / Total Assets 206.64b) |
| C: 0.07 (EBIT TTM 15.19b / Avg Total Assets 212.99b) |
| D: 0.68 (Book Value of Equity 80.67b / Total Liabilities 117.94b) |
| Altman-Z'' Score: 1.61 = BB |
Beneish M -3.09
| DSRI: 1.05 (Receivables 5.50b/4.42b, Revenue 88.66b/74.97b) |
| GMI: 0.82 (GM 55.92% / 45.83%) |
| AQI: 0.92 (AQ_t 0.77 / AQ_t-1 0.84) |
| SGI: 1.18 (Revenue 88.66b / 74.97b) |
| TATA: -0.03 (NI 9.85b - CFO 15.19b) / TA 206.64b) |
| Beneish M-Score: -3.09 (Cap -4..+1) = AA |
What is the price of BUD shares?
Over the past week, the price has changed by +5.76%, over one month by +18.92%, over three months by +20.80% and over the past year by +53.21%.
Is BUD a buy, sell or hold?
- StrongBuy: 5
- Buy: 5
- Hold: 3
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the BUD price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 78.1 | 3% |
| Analysts Target Price | 78.1 | 3% |
| ValueRay Target Price | 80.5 | 6.2% |
BUD Fundamental Data Overview February 07, 2026
P/E Forward = 17.762
P/S = 2.4867
P/B = 1.7942
P/EG = 1.49
Revenue TTM = 88.66b USD
EBIT TTM = 15.19b USD
EBITDA TTM = 24.56b USD
Long Term Debt = 68.97b USD (from longTermDebt, last fiscal year)
Short Term Debt = 1.45b USD (from shortTermDebt, last fiscal year)
Debt = 72.17b USD (from shortLongTermDebtTotal, last fiscal year)
Net Debt = 61.00b USD (from netDebt column, last fiscal year)
Enterprise Value = 210.53b USD (145.73b + Debt 72.17b - CCE 7.37b)
Interest Coverage Ratio = 1.79 (Ebit TTM 15.19b / Interest Expense TTM 8.48b)
EV/FCF = 18.07x (Enterprise Value 210.53b / FCF TTM 11.65b)
FCF Yield = 5.53% (FCF TTM 11.65b / Enterprise Value 210.53b)
FCF Margin = 13.14% (FCF TTM 11.65b / Revenue TTM 88.66b)
Net Margin = 11.10% (Net Income TTM 9.85b / Revenue TTM 88.66b)
Gross Margin = 55.92% ((Revenue TTM 88.66b - Cost of Revenue TTM 39.08b) / Revenue TTM)
Gross Margin QoQ = 56.41% (prev 56.29%)
Tobins Q-Ratio = 1.02 (Enterprise Value 210.53b / Total Assets 206.64b)
Interest Expense / Debt = 1.25% (Interest Expense 903.0m / Debt 72.17b)
Taxrate = 32.14% (726.0m / 2.26b)
NOPAT = 10.31b (EBIT 15.19b * (1 - 32.14%))
Current Ratio = 0.70 (Total Current Assets 23.00b / Total Current Liabilities 33.07b)
Debt / Equity = 0.79 (Debt 72.17b / totalStockholderEquity, last quarter 91.41b)
Debt / EBITDA = 2.48 (Net Debt 61.00b / EBITDA 24.56b)
Debt / FCF = 5.24 (Net Debt 61.00b / FCF TTM 11.65b)
Total Stockholder Equity = 84.76b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.62% (Net Income 9.85b / Total Assets 206.64b)
RoE = 11.62% (Net Income TTM 9.85b / Total Stockholder Equity 84.76b)
RoCE = 9.88% (EBIT 15.19b / Capital Employed (Equity 84.76b + L.T.Debt 68.97b))
RoIC = 6.83% (NOPAT 10.31b / Invested Capital 151.01b)
WACC = 4.76% (E(145.73b)/V(217.90b) * Re(6.70%) + D(72.17b)/V(217.90b) * Rd(1.25%) * (1-Tc(0.32)))
Discount Rate = 6.70% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -0.75%
[DCF Debug] Terminal Value 86.31% ; FCFF base≈11.26b ; Y1≈11.23b ; Y5≈11.83b
Fair Price DCF = 169.6 (EV 352.96b - Net Debt 61.00b = Equity 291.97b / Shares 1.72b; r=5.90% [WACC]; 5y FCF grow -0.88% → 2.90% )
EPS Correlation: -12.10 | EPS CAGR: -43.00% | SUE: -4.0 | # QB: 0
Revenue Correlation: -12.57 | Revenue CAGR: -15.51% | SUE: -0.02 | # QB: 0
EPS next Year (2026-12-31): EPS=4.17 | Chg30d=-0.011 | Revisions Net=+0 | Growth EPS=+14.2% | Growth Revenue=+5.7%